FindTrial
Sign In

Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease

Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease - Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000035602
Enrollment
20
Registered
2019-01-21
Start date
2019-01-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

hydrogen gas16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation placebo gas 16 weeks inhalation two times of the inhalation for 60 min

Sponsors

Juntendo University Koshigaya Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: MDS Parkinson's disease criteria modified Hoehn and Yahr stage 0~3 without dementia without lung disease

Exclusion criteria

Exclusion criteria: Parkinsonism except Parkinson's disease modified Hoehn and Yahr stage 4~5 with dementia with lung disease with malignant tumor

Design outcomes

Primary

MeasureTime frame
The change of MDS-UPDRS from the baseline to 16th week between hydrogen gas and placebo gas—

Secondary

MeasureTime frame
The change of parts of MDS-UPDRS PDQ-39 18-OHdG N1,N8-diacetylspermidine from the baseline to 16th week between hydrogen gas and placebo gas—

Countries

Japan

Contacts

Public ContactAsako Yoritaka

Juntendo University Koshigaya Hospital Neurology

ayori@juntendo.ac.jp0489750321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026